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Empagran S.A. v. F. Hoffman-Laroche, Ltd.:
DC Circuit Restricts Reach of US Antitrust
Laws over Injuries Sustained in Foreign
Commerce
Leon Greenfield and David Olsky

Abstract

On June 28, 2005, the US Court of Appeals for the District of Columbia issued
an important opinion on the extraterritorial reach of the US antitrust laws in Empagran S.A. v. F. Hoffman-Laroche, Ltd. The court held, on remand from the
Supreme Court, that plaintiffs injured outside US commerce cannot bring antitrust
suits in US courts unless the US effects of the anticompetitive conduct at issue are
the proximate cause of their injuries. The decision construes narrowly the circumstances under which plaintiffs may be able to sue in US courts for injuries suffered
in foreign commerce.
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Empagran S.A. v. F. Hoffman-Laroche, Ltd.:
DC Circuit Restricts Reach of US Antitrust Laws
Over Injuries Sustained in Foreign Commerce
On June 28, 2005, the US Court of Appeals
for the District of Columbia issued an
important opinion on the extraterritorial
reach of the US antitrust laws in Empagran
S.A. v. F. Hoffman-Laroche, Ltd.1 The court
held, on remand from the Supreme Court,
that plaintiffs injured outside US commerce
cannot bring antitrust suits in US courts
unless the US effects of the anticompetitive
conduct at issue are the proximate cause
of their injuries. The decision construes
narrowly the circumstances under which
plaintiffs may be able to sue in US courts
for injuries suffered in foreign commerce.
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Empagran was a class action brought by
plaintiffs that had purchased vitamins
overseas. They alleged that vitamin
manufacturers had participated in
a global price-ﬁxing conspiracy that
raised prices both for the vitamins they
purchased overseas and for the vitamins
that others purchased in US commerce.
The critical issue in Empagran was
whether the Foreign Trade and Antitrust
Improvement Acts of 1982 (FTAIA)
barred the purchasers from bringing
antitrust claims in US courts. The FTAIA
prohibits antitrust suits for transactions
in foreign commerce—that is, commerce

taking place entirely outside the United
States—unless the plaintiff can show that:
(1) The alleged harmful conduct
had a “direct, substantial, and
reasonably foreseeable effect”
on US commerce; and
(2) The effect on US commerce gave rise
to “a” claim under the Sherman Act.
Last year, in a closely watched decision,
F. Hoffman-Laroche, Ltd. v. Empagran S.A.,
542 US 155 (2004), the Supreme Court
held that the FTAIA barred the purchasers
from bringing their claims in US courts if
their injuries were “independent” of the
conspiracy’s effects in US commerce. The
Court did not, however, ﬁnally resolve the
case. The purchasers had argued to the
Court that their injuries were “linked” to
the US effects of the conspiracy because
manufacturers needed to keep prices
high in the United States to prevent US
vitamin purchasers from proﬁtably reselling
vitamins in foreign countries (and thereby
undermining the success of the conspiracy
in those countries). The purchasers
argued that their injuries were therefore
not “independent” of the conspiracy’s
effects in US commerce. The Supreme
Court remanded the case to the DC

Waltham
Washington

1. Wilmer Cutler Pickering Hale and Dorr LLP represented one of the appellees before the court.

Hosted by The Berkeley Electronic Press

Following the Supreme Court’s Empagran
decision, there was great uncertainty
about the scope and practical effects of
the potential opening left for plaintiffs
purchasing outside the United States to
sue in US courts for injuries that were
not “independent” of the conspiracy’s US
effects. In particular, the Court had failed
to deﬁne what “independent” meant. The
question became whether the courts
would deﬁne the term “independent” so as
to give rise to US jurisdiction whenever a
purchaser in foreign commerce could allege
that its injuries were in some way caused by
the conspiracy’s effects in US commerce.

conspiracy—i.e., the artiﬁcially inﬂated
prices of vitamins sold in foreign countries.
The court recognized that the ﬁxing of
vitamin prices in the United States may
have facilitated the manufacturers’ ﬁxing of
vitamin prices in foreign countries, and that
the manufacturers may have foreseen or
intended this result. It concluded, however,
that the artiﬁcially inﬂated vitamin prices
in the United States were only an indirect
cause—not a “proximate cause”—of the
purchasers’ injury in overseas markets.
There was no “direct tie” between the US
effects and the injuries that the purchasers
sustained. Accordingly, the effects of the
conspiracy on US commerce did not
“give rise to” the purchasers’ claims as
required by the FTAIA, and the purchasers
were barred from suing in US courts.

The DC Circuit Opinion

Implications of the Decision

On remand, the DC Circuit held that the
purchasers’ injuries were not sufﬁciently
linked to the alleged conspiracy’s effect on
US commerce to support US jurisdiction
over their antitrust claims. The court ﬁrst
observed that antitrust injuries sustained
in foreign commerce may be redressed in
US Courts in only limited circumstances.
To obtain relief, plaintiffs must show
that their injuries bear a “direct causal
relationship” to the US effects of the
alleged anticompetitive conduct. In other
words, the US effects of anticompetitive
conduct must be the “proximate cause”
of the plaintiffs’ injury rather than simply
a “but-for” cause thereof. The court
noted that this interpretation of the FTAIA
accords with the principles of “prescriptive
comity”—i.e., “the respect sovereign
nations afford each other by limiting the
reach of their laws”—that the Supreme
Court endorsed in its Empagran opinion.

The DC Circuit’s decision on remand
suggests that courts of appeal may
construe the term “independent” so as
to bar under the FTAIA claims for injuries
suffered in foreign commerce that are not
directly tied to effects in US commerce.
The DC Circuit’s decision, along with the
Second Circuit’s decision in Sniado v. Bank
Austria AG, 378 F.3d 210 (2d Cir. 2004),
indicate that the appellate courts are
taking very seriously the comity concerns
that the Supreme Court articulated in its
Empagran opinion, and that they will be
reluctant to extend US jurisdiction over
antitrust claims to transactions taking
place strictly in foreign commerce.

Circuit to determine the validity of this
argument (and if the argument had been
properly preserved in the lower courts).

The DC Circuit then held that the US
courts lacked jurisdiction over the
purchasers’ claims because the US effects
of the manufacturers’ conspiracy were
not the proximate cause of the purchasers’
alleged injuries. The court observed that
the direct cause (and thus the proximate
cause) of the purchasers’ injuries was
in fact the foreign effects of the global
2

It bears noting, however, that the DC
Circuit’s decision in Empagran is not the
last word in the long-running debate about
what exactly the FTAIA means. At least one
district court decision, In re Monosodium
Glutamate Antitrust Litigation, 2005 WL
1080790 (D. Minn. May 2, 2005), held that
plaintiffs purchasing fungible goods overseas
had sufﬁciently alleged a direct tie between
their injuries and the US effects of a global
price-ﬁxing conspiracy so as to overcome
the FTAIA’s jurisdictional limitations.
Furthermore, the plaintiffs in Empagran will
probably seek rehearing from an en banc
http://law.bepress.com/wilmer/art13
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panel of the DC Circuit or ﬁle a petition
for certiorari with the Supreme Court. We
expect that the DC Circuit’s “proximate
cause” standard is likely to prove inﬂuential
in future cases involving the FTAIA, but
the denouement of the whole FTAIA
saga may not yet have been written.
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